Alkem Laboratories informs about press release

25 Sep 2023 Evaluate

Alkem Laboratories has informed that the Company and Biosergen AB (‘Biosergen’), have entered into a co-development and license agreement for the development and commercialization of Biosergen’s novel polyene macrolide antifungal product BSG005 for the treatment of severe invasive fungal disease. A press release in this regard is enclosed.

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories Share Price

5689.30 77.65 (1.38%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×